Skye Bioscience to Present at TD Cowen Health Care Conference
Rhea-AI Summary
Skye Bioscience (Nasdaq: SKYE), a clinical-stage biopharmaceutical company specializing in obesity and metabolic health disorders treatments, has announced its participation in the TD Cowen 45th Annual Health Care Conference.
CEO Punit Dhillon will deliver a corporate overview and be available for one-on-one meetings during the event. The presentation is scheduled for Wednesday, March 5, 2025, from 11:10 AM to 11:40 AM ET in Boston, MA. Interested parties can access both live and archived versions of the webcast through Skye's website.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, SKYE declined 1.57%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that Punit Dhillon, Chief Executive Officer, will present a corporate overview and be available for 1x1 meetings at the TD Cowen 45th Annual Health Care Conference.
- Presentation Date: Wednesday, March 5, 2025
- Time: 11:10 AM – 11:40 AM ET
- Location: Boston, MA
A live and archived webcast will be accessible on Skye’s website.
About Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.
CONTACTS
Investor Relations
ir@skyebioscience.com
(858) 410-0266
LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306
Media Inquiries
LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(628) 234-3889
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “plans,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company’s periodic filings with the Securities and Exchange Commission, including in the “Risk Factors” section of Skye’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.
FAQ
When is Skye Bioscience presenting at the TD Cowen Health Care Conference in 2025?
How can investors watch Skye Bioscience's presentation at the TD Cowen conference?
What is the focus of Skye Bioscience's research and development?
Will Skye Bioscience (SKYE) offer individual investor meetings at the TD Cowen conference?
